FDA Is Pursuing Its Own Pharma Fraud Investigations; DoJ Nets $2.5 Bil. In FY 2010
Executive Summary
One sign that the government is zealously going after the pharmaceutical industry for health care fraud is the line up of criminal investigations FDA has initiated.
You may also be interested in...
FDA Opened 16 Health Care Fraud Investigations In FY 2011; DoJ Net Tops $4 Billion
HHS and the Department of Justice note actions taken last year in their Health Care Fraud and Abuse Control Program Annual Report for fiscal year 2011; enforcement actions net a record sum.
Off-Label Prosecution May Be Where FDA "Parks" Aggressive Enforcement Tools First
FDA appears likely to target flagrant off-label promotion in its first cases under new procedures for using the Park Doctrine and strict liability statutes to prosecute corporate executives and others.
Novartis Settlement Encompasses Whistleblower Claims Of Kickbacks For Diovan Prescribing
The company agrees to pay $422.5 million to resolve civil and criminal claims related to off-label use and kickbacks, including allegations that it paid doctors' speaking and consulting fees based upon the volume of prescriptions they wrote for its hypertension drugs.